CN114129654B

CN114129654B - Pharmaceutical composition and preparation for treating cow mastitis

Info

Publication number: CN114129654B
Application number: CN202111585327.6A
Authority: CN
Inventors: 王振宇; 王志学
Original assignee: Liaoning Institute of Science and Technology
Current assignee: Liaoning Institute of Science and Technology
Priority date: 2021-12-22
Filing date: 2021-12-22
Publication date: 2022-12-06
Anticipated expiration: 2041-12-22
Also published as: CN114129654A

Abstract

Provides a pharmaceutical composition and a preparation for treating cow mastitis. The medicine composition is prepared from the following traditional Chinese medicine raw materials in parts by weight: 10-40 parts of radix bupleuri, 10-40 parts of radix scutellariae, 10-40 parts of pericarpium citri reticulatae viride, 10-50 parts of radix paeoniae rubra, 10-40 parts of cowherb seed, 10-40 parts of rhizoma anemarrhenae, 10-80 parts of radix astragali, 10-80 parts of radix rehmanniae and 10-40 parts of radix salviae miltiorrhizae. The pharmaceutical composition has the functions of soothing liver, regulating qi, promoting lactation, diminishing inflammation and the like, and can realize the effect of treating various types of cow mastitis. In addition, the invention is not suitable for cows in gestation period, and has no obvious toxic or side effect on cows in other periods. In addition, the medicine composition provided by the invention can be prepared into decoction or powder, and can be used for well treating cow mastitis.

Description

Pharmaceutical composition and preparation for treating cow mastitis

Technical Field

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating cow mastitis and a preparation method thereof.

Background

Cow mastitis is a common multiple disease worldwide and is closely related to cow feeding and environment. Generally, the annual incidence of mastitis in cows is 20% to 50% (cythia M. Kahn, scotline group [ M ]. Chinese agriculture press, 2015). According to the statistics of the American cow mastitis conference, the loss caused by cow mastitis accounts for about 1/3 of the total value of dairy production, and the economic loss caused by cow mastitis accounts for about 20 billion dollars each year in the United states. Cow mastitis is classified into dominant mastitis and recessive mastitis. The dominant mastitis is mainly characterized in that the mammary duct of a cow is blocked and dilated due to various reasons, plasma cells in peripheral adipose tissues are infiltrated, the skin of the breast is provided with lumps, the boundaries of the lumps are clear, and the skin temperature rise can reach most of the breasts. Recessive mastitis is mostly caused by the conditions of milk secretion disturbance or the existence of particles or agglomeration and the like in the value of secreted milk due to various reasons, so that the number of somatic cells in milk is increased, and cows generate inferior milk. The main pathogens that cause mastitis and reduced milk production in cows are bacteria, viruses, fungi, algae, etc. Additionally, cow mastitis may also result from mechanical damage to, for example, the cow's breasts and/or nipples.

The existing methods for treating mastitis are mainly antibiotic therapy. As taught in the merck manual of veterinary medicine, a treatment regimen of antibiotic + dexamethasone was used to treat mastitis in cows in the dry period (cythia M. Kahn, scotline group [ M ]. Chinese agriculture press 2015). But no description is given of the treatment of mastitis in cows during the milk production period. In addition, if antibiotics are not properly selected during treatment, inflammation worsens, mammary organic lesions and even cow death results. In addition, practical treatment or feeding experience shows that cows are often shown to have reduced milk yield or enter a dry milk period in advance after being cured by antibiotics, and milk is required to be destroyed or subjected to other harmless treatment because the milk contains the antibiotics which are unqualified milk.

At present, the treatment of mastitis in some dairy farms is mostly limited to treatment by antibiotics when the life of cows is threatened, but is not treated for cows with lighter symptoms, so that milk containing antibiotics is prevented from being mixed into a milk tank. Therefore, in actual production, the treatment of cow mastitis requires safety and effectiveness, and the treatment medicine cannot contain artificially synthesized or microbial fermented antibiotics. The traditional Chinese medicine method is adopted to treat cow mastitis, particularly cow mastitis, so that the aims can be effectively fulfilled. But also the treatment scheme of traditional Chinese medicine is really good at solving the complex diseases. The preparation is summarized through long-term experiments, and has good curative effect on cow mastitis.

Disclosure of Invention

The invention aims to provide a Chinese medicinal formula for treating cow mastitis without using artificially synthesized antibiotics or microbiologically derived antibiotics. The traditional Chinese medicine prescription comprises a pharmaceutical composition for treating cow mastitis and a preparation method thereof.

The invention also aims to provide a method for treating cow mastitis without using artificially synthesized antibiotics or microbiogenic antibiotics, and only using a traditional Chinese medicine prescription, so that the cow milk is prevented from containing artificially synthesized antibiotics or microbiogenic antibiotics, and the aim of treating cow mastitis without antibiotics is fulfilled. The traditional Chinese medicine prescription comprises a traditional Chinese medicine raw material composition and a medicine composition for treating cow mastitis without obvious side effects and a preparation method of the medicine composition for treating cow mastitis.

According to one aspect of the invention, a pharmaceutical composition for treating cow mastitis is provided, wherein the pharmaceutical composition is prepared from the following traditional Chinese medicine raw materials in parts by weight: 10-40 parts of radix bupleuri, 10-40 parts of radix scutellariae, 10-40 parts of pericarpium citri reticulatae viride, 10-50 parts of radix paeoniae rubra, 10-40 parts of cowherb seed, 10-40 parts of rhizoma anemarrhenae, 10-80 parts of radix astragali, 10-80 parts of radix rehmanniae and 10-40 parts of radix salviae miltiorrhizae.

According to an exemplary embodiment of the invention, the pharmaceutical composition is prepared from the following traditional Chinese medicine raw materials in parts by weight: 10 parts of bupleurum, 10 parts of scutellaria, 20 parts of green tangerine peel, 10 parts of red paeony root, 10 parts of cowherb seed, 10 parts of rhizoma anemarrhenae, 10 parts of astragalus, 10 parts of radix rehmanniae and 10 parts of salvia miltiorrhiza.

According to an exemplary embodiment of the invention, the pharmaceutical composition is prepared from the following traditional Chinese medicine raw materials in parts by weight: 30 parts of radix bupleuri, 30 parts of radix scutellariae, 30 parts of pericarpium citri reticulatae viride, 10 parts of radix paeoniae rubra, 10 parts of cowherb seed, 30 parts of rhizoma anemarrhenae, 20 parts of radix astragali, 20 parts of radix rehmanniae and 20 parts of radix salviae miltiorrhizae.

According to an exemplary embodiment of the invention, the pharmaceutical composition is prepared from the following traditional Chinese medicine raw materials in parts by weight: 40 parts of bupleurum, 40 parts of scutellaria, 30 parts of green tangerine peel, 10 parts of red peony root, 10 parts of cowherb seed, 40 parts of rhizoma anemarrhenae, 40 parts of astragalus, 40 parts of radix rehmanniae and 40 parts of salvia miltiorrhiza.

According to an exemplary embodiment of the invention, the pharmaceutical composition is prepared from the following traditional Chinese medicine raw materials in parts by weight: 40 parts of bupleurum, 40 parts of scutellaria, 30 parts of green tangerine peel, 50 parts of red peony root, 10 parts of cowherb seed, 40 parts of rhizoma anemarrhenae, 80 parts of astragalus, 80 parts of radix rehmanniae and 40 parts of salvia miltiorrhiza.

According to an exemplary embodiment of the invention, the traditional Chinese medicine raw materials further comprise at least one of 1-10 parts by weight of cassia twig, 1-10 parts by weight of schizonepeta, 1-10 parts by weight of asarum, 1-10 parts by weight of ginger, 1-10 parts by weight of divaricate saposhnikovia root, 1-10 parts by weight of angelica dahurica, 1-10 parts by weight of mulberry leaf, 1-10 parts by weight of duckweed, 1-10 parts by weight of fermented soybean, 1-10 parts by weight of mung bean, 1-10 parts by weight of glabrous greenbrier rhizome, 1-10 parts by weight of immature bitter orange, 1-10 parts by weight of ligusticum wallichii, 1-10 parts by weight of salvia chinensis, 1-10 parts by weight of suberect spatholobus stem, 1-10 parts by weight of myrrh, 1-10 parts by weight of pubescent holly root and 1-10 parts by weight of cattail pollen.

According to an exemplary embodiment of the invention, the pharmaceutical composition is prepared from the following traditional Chinese medicine raw materials in parts by weight: 10 parts of radix bupleuri, 10 parts of radix scutellariae, 20 parts of pericarpium citri reticulatae viride, 10 parts of radix paeoniae rubra, 10 parts of cowherb seed, 10 parts of rhizoma anemarrhenae, 10 parts of radix astragali, 10 parts of radix rehmanniae, 10 parts of radix salviae miltiorrhizae, 1-5 parts of cassia twig, 1-5 parts of asarum, 1-5 parts of radix saposhnikoviae, 1-5 parts of duckweed, 1-5 parts of fermented soybean, 1-5 parts of mung bean, 1-5 parts of rhizoma smilacis glabrae, 1-5 parts of myrrh, 1-5 parts of pubescent holly root and 1-5 parts of pollen typhae.

According to another aspect of the present invention, there is provided a pharmaceutical composition for treating cow mastitis, wherein the pharmaceutical composition is prepared from the following traditional Chinese medicine raw materials by weight: 10 parts of radix bupleuri, 10 parts of scutellaria baicalensis, 20 parts of pericarpium citri reticulatae viride, 10 parts of radix paeoniae rubra, 10 parts of cowherb seed, 10 parts of rhizoma anemarrhenae, 10 parts of astragalus membranaceus, 10 parts of radix rehmanniae, 10 parts of salvia miltiorrhiza, 3-5 parts of radix angelicae, 3-5 parts of folium mori, 3-5 parts of duckweed, 3-5 parts of fermented soybean, 3-5 parts of mung bean, 1-10 parts of rhizoma smilacis glabrae, 1-10 parts of immature bitter orange, 1-5 parts of pubescent holly root and 1-5 parts of pollen typhae.

According to another aspect of the invention, a pharmaceutical composition for treating cow mastitis is provided, wherein the pharmaceutical composition is prepared from the following traditional Chinese medicine raw materials in parts by weight: 10 parts of radix bupleuri, 10 parts of scutellaria baicalensis, 20 parts of pericarpium citri reticulatae viride, 10 parts of radix paeoniae rubra, 10 parts of cowherb seed, 10 parts of rhizoma anemarrhenae, 10 parts of astragalus membranaceus, 10 parts of radix rehmanniae, 10 parts of salvia miltiorrhiza, 3-5 parts of radix angelicae, 3-5 parts of folium mori, 3-5 parts of duckweed, 3-5 parts of fermented soybean, 3-5 parts of mung bean, 1-10 parts of rhizoma smilacis glabrae, 1-10 parts of immature bitter orange, 1-5 parts of pubescent holly root and 1-5 parts of pollen typhae.

According to another aspect of the invention, a pharmaceutical composition for treating cow mastitis is provided, wherein the pharmaceutical composition is prepared from the following traditional Chinese medicine raw materials in parts by weight: 10 parts of radix bupleuri, 10 parts of radix scutellariae, 20 parts of pericarpium citri reticulatae viride, 10 parts of radix paeoniae rubra, 10 parts of cowherb seed, 10 parts of rhizoma anemarrhenae, 10 parts of radix astragali, 10 parts of radix rehmanniae, 10 parts of radix salviae miltiorrhizae, 3-5 parts of radix angelicae, 3-5 parts of folium mori, 3-5 parts of duckweed, 3-5 parts of fermented soybean, 3-5 parts of mung bean, 1-10 parts of rhizoma smilacis glabrae, 1-10 parts of immature bitter orange, 1-5 parts of pubescent holly root and 1-5 parts of pollen typhae.

According to a further aspect of the present invention, there is provided a decoction for treating cow mastitis, the decoction being obtained by: the preparation method comprises the following steps of adding the following traditional Chinese medicine raw materials into water, soaking for a preset time, boiling for a preset time, cooling and filtering to obtain a decoction, wherein the traditional Chinese medicine raw materials comprise the following components in parts by weight: 10-40 parts of radix bupleuri, 10-40 parts of radix scutellariae, 10-40 parts of pericarpium citri reticulatae viride, 10-50 parts of radix paeoniae rubra, 10-40 parts of cowherb seed, 10-40 parts of rhizoma anemarrhenae, 10-80 parts of radix astragali, 10-80 parts of radix rehmanniae and 10-40 parts of radix salviae miltiorrhizae.

According to an embodiment of the present invention, the Chinese medicinal materials are pulverized to 300 mesh before the step of adding the Chinese medicinal materials to water.

According to still another aspect of the present invention, there is provided a powder for treating cow mastitis, the powder being prepared by: drying various traditional Chinese medicine raw materials, pulverizing into 120 meshes, mixing, aging and sterilizing at 110-115 ℃ for 10-30min to obtain powder, wherein the traditional Chinese medicine raw materials comprise the following components in parts by weight: 10-40 parts of radix bupleuri, 10-40 parts of radix scutellariae, 10-40 parts of pericarpium citri reticulatae viride, 10-50 parts of radix paeoniae rubra, 10-40 parts of cowherb seed, 10-40 parts of rhizoma anemarrhenae, 10-80 parts of radix astragali, 10-80 parts of radix rehmanniae and 10-40 parts of radix salviae miltiorrhizae.

According to yet another aspect of the present invention, there is provided a formulation for treating mastitis in cows, which is prepared into a capsule, pill or tablet by the steps of: drying various traditional Chinese medicine raw materials, pulverizing into 120 meshes, mixing, aging and sterilizing at 110-115 ℃ for 10-30min, and then adding at least one of predetermined binder and auxiliary materials to obtain capsules, pills or tablets, wherein the traditional Chinese medicine raw materials comprise the following components in parts by weight: 10-40 parts of radix bupleuri, 10-40 parts of radix scutellariae, 10-40 parts of pericarpium citri reticulatae viride, 10-50 parts of radix paeoniae rubra, 10-40 parts of cowherb seed, 10-40 parts of rhizoma anemarrhenae, 10-80 parts of radix astragali, 10-80 parts of radix rehmanniae and 10-40 parts of radix salviae miltiorrhizae.

The pharmaceutical composition for treating cow mastitis according to the present invention has at least one of the following technical effects:

the pharmaceutical composition can play a role in promoting lactation, so that the mammary gland of the cow can secrete milk, and the possibility of curing severe mastitis of the cow is ensured.

The traditional Chinese medicine conservative treatment method solves the problem of bacterial breeding and proliferation caused by milk stasis, and effectively prevents abscess, ulceration, even septicemia and the like caused by bacterial proliferation and the like.

During the application process, drugs such as artificially synthesized antibiotics or microbial antibiotics are not used for treatment, so that adverse reactions caused by the corresponding drugs can be reduced. Meanwhile, the milk produced by the cow cured by the traditional Chinese medicine formula does not contain artificially synthesized antibiotics or microbiogenic antibiotics;

is suitable for cow mastitis in various stages, such as mass stage and ulceration stage of recessive mastitis and dominant mastitis;

the medicine is safe and effective, has no obvious side effect, can moderate the medicine property after being processed, reduces the body adverse reaction while ensuring the treatment effect, can nourish the cow mammary gland cells, and improves the cow mammary gland cell function;

changes the current situation that antibiotics are mainly used for treating cow mastitis, and provides a method for non-invasively treating cow mastitis in each stage. Different from antibiotic therapy, vaccine prevention and treatment, infrared therapy, nano-drug delivery technology or sonic therapy and the like, the traditional Chinese medicine formula can be used for drug delivery in a gastric perfusion mode, and can also be mixed in cow feed for drug delivery. If the traditional Chinese medicine formula of the invention is mixed in feed for administration, the cost brought by medical operation can be greatly saved, and the stress reaction of cows caused by the treatment operation of veterinarians or feeders can be effectively reduced. In the early experiments, the medicine powder is mostly mixed into the feed of the mastitis cows for administration, the mastitis cows can independently take the traditional Chinese medicine formula, and the effect is good if a single-groove feeding mode is adopted.

The Chinese medicinal prescription cannot be used for treating mastitis of the pregnant cows, and abortion of the pregnant cows may be caused in the treatment process.

Drawings

The illustrative exemplary embodiments will be more clearly understood from the following detailed description taken in conjunction with the accompanying drawings. In the drawings:

FIG. 1 shows the milk of the cow in example 3;

FIG. 2 shows the determination of mastitis in milk (CMT detection in milk) in example 3;

FIG. 3 shows the immunization of the cow in example 3, and the changes of the total number of leukocytes (A), the white blood cell groups (B, C), and the cytokine contents (D, E, F) in the blood of the cow in the 12-day test in example 3.

Detailed Description

The pharmaceutical composition for treating mastitis in cows and the preparation method thereof according to the present invention will now be described in detail.

Cow mastitis is a frequently encountered disease in clinical practice at present and can be divided into dominant (clinical type) mastitis and recessive (subclinical type) mastitis. Among them, clinical mastitis includes acute mastitis and chronic mastitis. Acute mastitis, affected milk chambers show red, swelling, heat and pain in different degrees, and meanwhile, the milk yield of cows is obviously reduced, even milk cannot be squeezed out due to the blockage of mammary glands. Chronic mastitis, milk produced by cows has different degrees of yellowing, stickiness, particulate matter and floccule, but generally has no other symptoms of the whole body. The milk produced by cow with mastitis is caused by the fact that the number of somatic cells in milk exceeds a specified value (4 x 10) ⁵ cell ml ^-1 ) And is identified as 2 types of milk or unqualified milk, even deteriorated milk. The quality of milk directly affects the quality of the dairy product and the health of the milk-fed calves. Thus, cow mastitis affects not only dairy production operations, but also breeding cows to feed young cows. For example, antibiotics and dexamethasone can be used to treat cows during their dry period according to the guidelines of the merck manual for veterinary use, and are highly effective (cythia M. Kahn, scottLine group [ M)]Chinese agriculture press 2015), but treatment of cows in the milk production period according to this method results in problems such as antibiotic residues in the milk. The consumption of milk containing antibiotics by young cattle usually causes diarrhea and other symptoms, and affects the health and growth development of the young cattle.

The traditional Chinese medicine is generally used for treating mastitis (acute mastitis) by methods such as a liver soothing and heat clearing method for soothing liver, regulating qi, removing carbuncle, blocking and removing blood stasis, a yang warming and stagnation dissipating method and the like, and female/dairy cows with different mastitis conditions are treated according to the treatment experience of Chinese veterinarians.

The causes of cow mastitis are complex, and cow mastitis can be caused by cow trauma, poor milking technique, poor sanitary environment, poor feeding management, cow hormone imbalance, breast defect and the like. Therefore, the inventor analyzes that cow mastitis is caused by stagnation of liver qi and stomach heat, and combines the clinical manifestations of cows on the pathogenesis, cow milk is accumulated in mammary glands to cause unsmooth secretion of mammary glands, pathogenic qi is transformed into heat to generate pathogenic toxin, the pathogenic toxin interacts with accumulated milk accumulated in mammary glands to aggravate the accumulation, pathogenic bacteria are bred to cause serious obstruction of mammary glands, even suppuration, ulceration and other symptoms occur, mild cow dry milk and mammary gland obstruction are caused, severe ulceration infection threatens cow life. Therefore, the invention provides a medicinal composition for treating cow mastitis by adopting a traditional Chinese medicine prescription in the whole course.

The dosage of Bupleurum (the name of Latin: bupleurum chinensis) is within the range of 10-40 weight portions, and the Bupleurum root has the functions of harmonizing exterior and interior and soothing liver.

The dosage of the scutellaria (the name of Latin: scutellaria Radix) is within the range of 10-40 parts by weight, and the scutellaria plays a role in clearing heat and drying dampness, and purging intense heat and removing toxicity.

The dosage of the Pericarpium Citri Reticulatae Viride (Latin name: citri particulate Pericarpium Viride) is within the range of 10-40 parts by weight, and the Pericarpium Citri Reticulatae Viride has the functions of soothing liver and breaking qi, and removing food retention and resolving stagnation in the invention.

The dosage of the red peony root (Latin name: paeoniae Radix Rubra) is within the range of 10-50 parts by weight, and the red peony root in the invention has the functions of liver depression, hypochondriac pain, carbuncle, swelling, sore and ulcer.

The dosage of the seed of cowherb (Latin name: vaccariae Semen) is within the range of 10-40 parts by weight, and the seed of cowherb has the functions of promoting blood circulation, stimulating the menstrual flow, promoting lactation and reducing swelling in the invention.

The dosage of the rhizoma anemarrhenae (the name of Latin: anemarrhena asphodeloides Bunge) is within the range of 10 to 40 weight parts, and the rhizoma anemarrhenae has the functions of clearing heat and purging fire, nourishing yin and reducing fire in the invention.

The usage amount of the Astragalus (Latin name: astragalus mongholicus Bunge) is within the range of 10-100 parts by weight, and the Astragalus plays the roles of benefiting vital qi, strengthening spleen and stomach, expelling pus, relieving pain and activating blood circulation in the invention.

The use amount of the radix rehmanniae (Latin name: rehmannia glutinosa (Gaetn.) Libosch.ex Fisch.et Mey) is within the range of 10-80 parts by weight, and the radix rehmanniae has the functions of clearing heat and cooling blood, nourishing yin and promoting the production of body fluid.

The use amount of the Salvia miltiorrhiza bge (the name of Latin: salvia militihiza bge.) is within the range of 10-40 parts by weight, and the Salvia miltiorrhiza bge in the invention has the effects of activating blood circulation, removing blood stasis, clearing channels, relieving pain, clearing heart, relieving restlessness, cooling blood and eliminating carbuncle.

The formula principle of the traditional Chinese medicine raw material composition is partially obtained according to the famous Chinese medicine and partially depends on practice. For instance, in Ben Cai Hui Yan, huang Qi can grow muscles when pus and blood of carbuncle are ulcerated and yang is not healed due to deficiency of qi; for yin sores which cannot be initiated and yang qi deficiency which cannot be ulcerated, huang Qi can support sepsis. According to the theories and practices of the predecessors, the astragalus can treat symptoms such as carbuncle, cellulitis, pus in the interior and the like. Zhuzhenheng (Yuan) "Rukui Lun in Gezhi Yu" considers that "Qing Pi is a medicine for qi distribution of liver and gallbladder meridians to dredge the two meridians and move qi", he thinks that Qing Pi can be used for treating acute mastitis. Chen Xie Yuan (Qing) is said that the prescription of chai Hu Shu Yin can treat liver qi and left hypochondriac pain.

In another exemplary embodiment of the present invention, the Chinese herbal materials may further include at least one of cassia twig, schizonepeta, asarum herb, ginger, ledebouriella root, dahurian angelica root, mulberry leaf, duckweed, fermented soybean, mung bean, glabrous greenbrier rhizome, immature bitter orange, chuanxiong rhizome, red ginseng, spatholobus stem, myrrh, pubescent holly root and cattail pollen.

The usage amount of the cassia twig (Latin name: cinnamomum cassia Presl) is within the range of 1-10 parts by weight, and the cassia twig has the effects of releasing muscles, warming meridians and promoting blood circulation and supporting yang and regulating qi.

Herba Schizonepetae (Latin name: schizonepetae Herba) with the dosage of 1-10 weight parts has the functions of regulating blood, detoxifying, removing blood stasis and stopping bleeding.

The dosage of the asarum (Latin name: asariradix Et Rhizoma) is 5-10 parts by weight, and the effects of relieving exterior syndrome, dispelling wind, dispelling cold, inducing resuscitation and relieving pain are achieved in the invention.

The usage amount of Rhizoma Zingiberis Recens (Latin name: zingiensis Rhizoma Recens) is in the range of 1-10 weight parts, and the effects of dispelling cold and relieving exterior syndrome in the invention are provided.

Radix sileris (Latin name: saposhnikoviae Radix) with the dosage of 1-10 parts by weight has the functions of relieving exterior syndrome, dispelling wind and eliminating dampness.

The Radix angelicae (latin name: ampelopsis Radix) is used in the range of 1-10 parts by weight, and has the functions of clearing away heat and toxic materials, eliminating carbuncles and dissipating stagnation.

The dosage of the mulberry leaf (Latin name: folium Mori) is within the range of 1-10 parts by weight, and the effects of the invention are bacteriostasis, anti-inflammation, antivirus, anticoagulation and detoxification.

The amount of Herba Spirodelae (Latin name: spirodelae Herba) is in the range of 1-10 weight parts, and the effect of the invention is diaphoresis, and,

Fermented soybean (Latin name: glycine max (L.) Merr. Fermented product of mature seed), the dosage is in the range of 1-10 parts by weight, and the effects of relieving exterior syndrome, relieving restlessness and dispersing stagnated heat in the invention are achieved.

The dosage of the mung bean (Latin name: semen Vignae Radiatae) is in the range of 1-10 parts by weight, and the mung bean has the function of clearing away heat and toxic materials.

Rhizoma smilacis glabrae (the name of Latin: smilax glabra Roxb) is used in the range of 1-10 parts by weight, and the effects of the invention are dehumidification and detoxification.

Immature bitter orange (Latin name: aurantiiI Fructus Immaturus) is used in the range of 1-10 weight parts, and the effect of the invention is anti-inflammatory; antibacterial and antiviral effects; anti-allergy reaction; antioxidation; relieving pain; central inhibition; and (4) clearing away heat.

The usage amount of the Ligusticum wallichii (Latin name: chuanxiong Rhizoma) is 1-10 parts by weight, and the effects of the invention are activating blood and promoting qi, dispelling wind and relieving pain.

The dosage of the purple ginseng (Latin name: bistortae Rhizoma) is 1-10 parts by weight, and the effects of promoting blood circulation, relieving pain, detoxifying and eliminating carbuncle in the invention are achieved.

The dosage of the Caulis Spatholobi (Latin name: spatholobi Caulis) is within the range of 1-10 parts by weight, and the Caulis Spatholobi has the effects of enriching blood, promoting blood circulation and dredging collaterals.

Myrrh (Latin name: commiphora myrrha (Nees) Engl.) with the dosage of 1-10 weight parts, the invention has the functions of eliminating stasis and relieving pain, detumescence and promoting granulation, carbuncle and sore and ulcer, etc.

Pubescent holly root (Latin name: ilex pubescens hook. Et Arn.) with the dosage of 1-10 weight parts has the functions of clearing away heat and toxic material, promoting blood circulation and removing obstruction in channels.

The usage amount of pollen Typhae (Latin name: typha angustis folaaL) is in the range of 1-10 weight parts, and the invention has the effects of stopping bleeding, removing blood stasis and treating stranguria.

If the cow has recessive mastitis or mild dominant mastitis, one or more of the Chinese medicinal materials can be added into the prescription according to different diseased conditions of the cow with mastitis. In an exemplary embodiment of the present invention, the pharmaceutical composition may be prepared from the following Chinese medicinal raw materials by weight: 10 parts of radix bupleuri, 10 parts of radix scutellariae, 20 parts of pericarpium citri reticulatae viride, 10 parts of radix paeoniae rubra, 10 parts of cowherb seed, 10 parts of rhizoma anemarrhenae, 10 parts of radix astragali, 10 parts of radix rehmanniae and 10 parts of radix salviae miltiorrhizae, and 3-5 parts of radix angelicae, 3-5 parts of folium mori, 3-5 parts of duckweed, 3-5 parts of fermented soybean, 3-5 parts of mung bean, 1-10 parts of rhizoma smilacis glabrae, 1-10 parts of immature bitter orange, 1-5 parts of pubescent holly root and 1-5 parts of pollen typhae as auxiliary materials.

If the cow has dominant (clinical) mastitis, one or more of the Chinese medicinal materials can be added into the formula according to different diseased conditions of the cow with mastitis. In an exemplary embodiment of the invention, the pharmaceutical composition can be prepared from the following traditional Chinese medicine raw materials in parts by weight: 30 parts of radix bupleuri, 30 parts of radix scutellariae, 30 parts of pericarpium citri reticulatae viride, 10 parts of radix paeoniae rubra, 10 parts of cowherb seed, 30 parts of rhizoma anemarrhenae, 20 parts of radix astragali, 20 parts of radix rehmanniae and 20 parts of radix salviae miltiorrhizae, and 3-5 parts of radix angelicae, 3-5 parts of folium mori, 3-5 parts of duckweed, 3-5 parts of fermented soybean, 3-5 parts of mung bean, 1-10 parts of rhizoma smilacis glabrae, 1-10 parts of immature bitter orange, 1-5 parts of pubescent holly root and 1-5 parts of pollen typhae as auxiliary materials.

If the cow presents severe clinical mastitis, according to an exemplary embodiment of the present invention, the pharmaceutical composition may be prepared from the following traditional Chinese medicine raw materials by weight: 40 parts of radix bupleuri, 40 parts of scutellaria baicalensis, 30 parts of pericarpium citri reticulatae viride, 50 parts of red paeony root, 10 parts of cowherb seed, 40 parts of rhizoma anemarrhenae, 80 parts of astragalus mongholicus, 80 parts of radix rehmanniae and 40 parts of salvia miltiorrhiza, and 3-5 parts of radix angelicae, 3-5 parts of folium mori, 3-5 parts of duckweed, 3-5 parts of fermented soybean, 3-5 parts of mung bean, 5-10 parts of rhizoma smilacis glabrae, 5-10 parts of immature bitter orange, 1-5 parts of pubescent holly root and 5 parts of pollen typhae are used as auxiliary materials.

In addition, in the present invention, the above-mentioned raw materials of the traditional Chinese medicine can be used in the form of decoction pieces which are subjected to primary processing or concocting treatment to meet quality standards. The above-mentioned Chinese medicinal materials may be used in the form of Chinese medicinal materials. The above-mentioned Chinese medicinal materials may be used in the form of Chinese medicinal materials and decoction pieces.

The pharmaceutical composition can be prepared by adopting a conventional preparation method of traditional Chinese medicines. For example, the preparation method of the decoction includes: putting the above Chinese medicinal materials (for example, in the form of decoction pieces) into a decocting container, adding water into the decocting container until the Chinese medicinal materials are submerged, decocting for a predetermined time, and filtering to obtain medicinal composition as decoction.

In an exemplary embodiment of the present invention, in the step of decocting for a predetermined time, the decocting vessel may be boiled with a strong fire and then decocted with a weak fire for 30 minutes.

The decoction for treating cow mastitis of the present invention can be obtained, for example, by the following method: placing Chinese medicinal materials (such as in form of decoction pieces) into decocting container, adding water into the decocting container, and soaking for 10-30 min; decocting for a predetermined time, and filtering to obtain decoction and residue, wherein the decoction can be administered by drenching or by cow. The decoction can also be used for preventing subclinical mastitis.

The powder for cow mastitis of the present invention can be obtained by the following method: drying and pulverizing the above Chinese medicinal materials in the form of decoction pieces to 120 mesh; mixing the pulverized Chinese medicinal materials, and aging and sterilizing at 100-110 deg.C for 10-30min to obtain powder.

In addition, the powder after curing treatment can also be processed into capsules, pills or tablets, and in this case, a proper amount of binder and/or auxiliary materials and the like are required to be added.

In addition, the powder, capsule, pill or tablet for treating cow mastitis of the present invention can treat cow mastitis.

The pharmaceutical composition for treating cow mastitis disclosed by the invention has the characteristics of suitability for various cow mastitis courses, simplicity and convenience in use, safety, reliability and the like.

The pharmaceutical composition for treating bovine mastitis and the preparation method thereof according to the present invention will be further illustrated below according to examples.

Example 1: decoction for treating recessive mastitis of dairy cow

The traditional Chinese medicine comprises the following raw materials: 10g of radix bupleuri, 10g of scutellaria baicalensis, 20g of green tangerine peel, 10g of red paeony root, 10g of cowherb seed, 10g of rhizoma anemarrhenae, 10g of astragalus membranaceus, 10g of radix rehmanniae and 10g of salvia miltiorrhiza.

The preparation method comprises the following steps: adding into a decocting vessel, adding water until the materials are submerged, soaking for 30-60min, boiling with strong fire, soaking for 20min, cooling, and filtering to obtain decoction and residue, wherein the decoction can be administered by cow.

Treatment and treatment effect determination

The standard for judging the treatment effect is to adopt California detection method (CMT method for short) to judge the disease course of cow mastitis, and the result is negative (t) (the somatic cell content in milk is less than 40 ten thousand cells ml) ^-1 ) Suspicious (n), weak positive (1), positive (2) and strong positive (3). One part of decoction (about 200 g/part) is taken per day by each cow, and the course of treatment is 5 days. The cow is administered the decoction for 5 days to treat recessive mastitis of cow. The quality of the milk produced by the decoction-treated cows was determined to be negative, indicating that the number of somatic cells in the milk produced by 7 treated cows was below the criterion for mastitis (the content of somatic cells in the milk produced by a cow was less than 40 ten thousand cells ml) ^-1 Cows were considered to have no mastitis symptoms), i.e. mastitis was cured in these 7 cows.

Example 2: powder for treating cow subclinical mastitis

The traditional Chinese medicine comprises the following raw materials: 30g of radix bupleuri, 30g of radix scutellariae, 30g of green tangerine peel, 10g of red peony root, 10g of cowherb seed, 30g of rhizoma anemarrhenae, 20g of radix astragali, 20g of radix rehmanniae, 20g of radix salviae miltiorrhizae, 1g of cassia twig, 1g of asarum, 1g of radix sileris, 1g of duckweed, 1g of fermented soybean, 1g of mung bean, 1g of rhizoma smilacis glabrae, 1g of myrrh, 1g of pubescent holly root and 1g of pollen typhae.

The preparation method comprises the following steps: after being processed by the processing method of the traditional Chinese medicine raw materials, the traditional Chinese medicine raw materials are crushed into 300 meshes and mixed for standby.

Treatment and treatment effect determination

One part of the powder (about 220 g/part) is taken per cow per day,administered by drenching for 5 days. By the CMT method. The detection result shows that after 10 treated cows are treated for 3 days, the somatic cell count of the milk produced by 7 cows is reduced to 40 ten thousand cells ml ^-1 Then, the quality of the milk is observed on the 5 th day, and the somatic cell content in the milk produced by 10 cows is less than 40 ten thousand cell ml ^-1 . It can be judged that the 7-cow mastitis treated by the traditional Chinese medicine powder of the invention is cured.

Example 3: powder for treating cow mastitis

The traditional Chinese medicine comprises the following raw materials: 40g of radix bupleuri, 40g of scutellaria baicalensis, 30g of green tangerine peel, 10g of red paeony root, 10g of cowherb seed, 40g of rhizoma anemarrhenae, 40g of astragalus membranaceus, 40g of radix rehmanniae, 40g of salvia miltiorrhiza, 3g of angelica dahurica, 3g of mulberry leaf, 3g of duckweed, 3g of fermented soybean, 3g of mung bean, 5g of rhizoma smilacis glabrae, 10g of immature bitter orange, 5g of pubescent holly root and 5g of pollen typhae.

The preparation method comprises the following steps: after being processed by the processing method of the traditional Chinese medicine raw materials, the traditional Chinese medicine raw materials are crushed into 300 meshes and mixed for later use.

One part of the powder (about 340 g/part) is taken by each cow per day, and the treatment course is 12 days. The following therapeutic effects can be observed upon detection. The test time is the mastitis high stage of the dairy cattle in three weeks, 20 dairy cattle with serious mastitis course are selected from dairy cattle disease groups for treatment, and 20 dairy cattle with mastitis are selected as a control group. During the treatment course of 12 days, the effective rate is observed to be 100 percent, and the cure rate is observed to be 95 percent. Except that the disease condition of one milk cow is serious initially, the disease condition of the milk cow is only relieved within a 12-day treatment course, the disease course of the milk is greatly improved from yellow floccule to liquid containing a certain amount of white particles, but the treatment effect of the milk is not continuously observed because other experiments are finished, so that the subsequent treatment results are not listed. After the treatment of the traditional Chinese medicine powder, all the homogalactic regions of the rest 19 cows are unobstructed, and the content of somatic cells in the milk meets the requirement, namely is reduced to 40 ten thousand cells ml ^-1 。

In the test, the clogging of the mammary region and the change of the course of mastitis of the cows in the treatment group and the blank control group were observed and recorded, and the results are shown in fig. 1 and 2 (example 3).

As shown in the experimental results of the embodiment 3 and the graphs 1 and 2, the traditional Chinese medicine powder can dredge the blocked milk area of the group cows within 7 days; meanwhile, the milk CMT test results of 19 cows in the treatment group showed negative, and 1 cow was weakly positive. In the control group, 4 cows had an increased course of mastitis leading to a blocked milk area, and 1 cow was self-healed on day 3 without treatment, but the mastitis had recurred on day 7, and the cow was convalescing to a sick herd. The results show that the traditional Chinese medicine powder can effectively dredge blocked milk areas and effectively reduce the number of somatic cells in milk.

As can be seen from the experimental results of example 3, fig. 3A shows that the total white blood cell count of the treated cows increased first (about 44% increase at day 5) and then decreased, and decreased to 54% of the initial value on day 12; the white blood cell count of the blank control group is 2.5-3.5 × 10 ⁶ cell mL ^-1 Interval, the fluctuation is small.

As can be seen from the experimental results of example 3, fig. 3B and C, the white blood cell proportion of the cows in the treatment group varied greatly during the treatment process, specifically, the proportion of the granulocytes in the blood increased greatly (from less than 5% to more than 20%) in the initial period of treatment (1 to 3 days), the proportion of the granulocytes increased further to 46% in the middle period of treatment (5 to 9), and then decreased to 33%; the white blood cells of the blank control group belong to the category, namely the proportion of the granulocytes and the lymphocytes in the white blood cells fluctuates slightly, the proportion of the lymphocytes is large (about 67-80%), and the proportion of the granulocytes is always lower than 20%.

As can be seen from the experimental results of example 3, FIGS. 3D, E and F, the IL-1 beta, IL-6 and TNF-alpha contents in the blood of the control group cows fluctuated less during the experiment; in the blood of the treated dairy cows, the contents of IL-1 beta, IL-6 and TNF-alpha are changed and are reduced firstly and then increased gradually. In the treatment process, TNF-alpha in the blood of the dairy cow reaches the lowest level at 3d, and is reduced by 68.8 percent compared with the initial level; at 5d, the IL-1 beta content in the milk cow blood is reduced to the minimum, which is reduced by 72.0 percent compared with the initial time; at 7d, IL-6 levels in the cow's blood were minimized, 65.9% less than initially.

Example 4: powder for treating mastitis of breeding cow

The traditional Chinese medicine comprises the following raw materials: 40g of radix bupleuri, 40g of radix scutellariae, 30g of green tangerine peel, 50g of red paeony root, 10g of cowherb seed, 40g of rhizoma anemarrhenae, 80g of radix astragali, 80g of radix rehmanniae, 40g of radix salviae miltiorrhizae, 5g of radix angelicae, 5g of folium mori, 5g of duckweed, 5g of fermented soybean, 5g of mung bean, 8g of rhizoma smilacis glabrae, 10g of immature bitter orange, 5g of pubescent holly root and 5g of pollen typhae.

Treatment and treatment effect determination

One part of powder (about 450 g/part) is taken every day by a cow breeding in the lactation period, and the treatment course is 15 days. In the early treatment stage, the mamma of the cows bred in the lactation period firstly appears swelling, after 5 days of treatment, the mamma swelling gradually subsides, the mamma becomes soft, the milk production function is gradually recovered, after 10 days of treatment, most cows bred in the lactation period produce milk to recover to normal, but part of the milk produced by the cows bred in the lactation period still contains flocculent precipitates and the like, after 15 days of treatment, the milk produced by the cows bred in the lactation period recovers to normal, and no particles exist in the milk. The observation after treatment shows that the breast of the breeding cow in the lactation period is red, swollen and painful and disappears, the breast recovers the milk production function, the quality of the produced milk is gradually changed from yellow floccule to normal milk, CMT detection of the milk produced by the breeding cow shows negative, and the mastitis of the breeding cow in the lactation period is judged to be cured.

Claims

1. The pharmaceutical composition for treating cow mastitis is characterized by being prepared from the following traditional Chinese medicine raw materials in parts by weight:

10-40 parts of radix bupleuri, 10-40 parts of radix scutellariae, 10-40 parts of pericarpium citri reticulatae viride, 10-50 parts of radix paeoniae rubra, 10-40 parts of cowherb seed, 10-40 parts of rhizoma anemarrhenae, 40-80 parts of radix astragali, 40-80 parts of radix rehmanniae and 10-40 parts of radix salviae miltiorrhizae.

2. The pharmaceutical composition according to claim 1, which is prepared from the following traditional Chinese medicine raw materials in parts by weight: 40 parts of bupleurum, 40 parts of scutellaria, 30 parts of green tangerine peel, 10 parts of red peony root, 10 parts of cowherb seed, 40 parts of rhizoma anemarrhenae, 40 parts of astragalus, 40 parts of radix rehmanniae and 40 parts of salvia miltiorrhiza.

3. The pharmaceutical composition according to claim 1, which is prepared from the following traditional Chinese medicine raw materials in parts by weight: 40 parts of bupleurum, 40 parts of scutellaria, 30 parts of green tangerine peel, 50 parts of red peony root, 10 parts of cowherb seed, 40 parts of rhizoma anemarrhenae, 80 parts of astragalus, 80 parts of radix rehmanniae and 40 parts of salvia miltiorrhiza.

4. The pharmaceutical composition for treating cow mastitis is characterized by being prepared from the following traditional Chinese medicine raw materials in parts by weight: 40 parts of radix bupleuri, 40 parts of radix scutellariae, 30 parts of pericarpium citri reticulatae viride, 10 parts of radix paeoniae rubra, 10 parts of cowherb seed, 40 parts of rhizoma anemarrhenae, 40 parts of radix astragali, 40 parts of radix rehmanniae, 40 parts of radix salviae miltiorrhizae, 3 parts of radix angelicae, 3 parts of folium mori, 3 parts of duckweed, 3 parts of fermented soybean, 3 parts of mung bean, 5 parts of rhizoma smilacis glabrae, 10 parts of fructus aurantii immaturus, 5 parts of pubescent holly root and 5 parts of pollen typhae.

5. The pharmaceutical composition for treating cow mastitis is characterized by being prepared from the following traditional Chinese medicine raw materials in parts by weight: 40 parts of radix bupleuri, 40 parts of radix scutellariae, 30 parts of pericarpium citri reticulatae viride, 50 parts of radix paeoniae rubra, 10 parts of cowherb seed, 40 parts of rhizoma anemarrhenae, 80 parts of radix astragali, 80 parts of radix rehmanniae, 40 parts of radix salviae miltiorrhizae, 5 parts of radix angelicae, 5 parts of folium mori, 5 parts of duckweed, 5 parts of fermented soybean, 5 parts of mung bean, 8 parts of rhizoma smilacis glabrae, 10 parts of fructus aurantii immaturus, 5 parts of pubescent holly root and 5 parts of pollen typhae.

6. A decoction for treating cow mastitis, which is obtained by the following steps:

soaking the following Chinese medicinal materials in water for a predetermined time, boiling for a predetermined time, cooling, filtering to obtain decoction,

the traditional Chinese medicine comprises the following raw materials in parts by weight: 10-40 parts of radix bupleuri, 10-40 parts of radix scutellariae, 10-40 parts of pericarpium citri reticulatae viride, 10-50 parts of radix paeoniae rubra, 10-40 parts of cowherb seed, 10-40 parts of rhizoma anemarrhenae, 40-80 parts of radix astragali, 40-80 parts of radix rehmanniae and 10-40 parts of radix salviae miltiorrhizae.

7. The decoction of claim 6, wherein the Chinese medicinal materials are crushed to 200-300 mesh before the step of adding the Chinese medicinal materials to water.

8. Powder for treating cow mastitis, wherein the powder is prepared by the following steps:

drying the raw materials, pulverizing to 80-120 meshes, mixing, aging and sterilizing at 110-115 deg.C for 10-30min to obtain powder,

9. A preparation for treating cow mastitis is characterized in that the preparation is prepared into capsules, pills or tablets by the following steps,

drying the raw materials, pulverizing to 80-120 mesh, mixing, aging and sterilizing at 110-115 deg.C for 10-30min, adding at least one of predetermined adjuvants to obtain capsule, pill or tablet,